NorthWest Biotherapeutics Inc (NWBO)

[j e d]

You're stuck focusing on the "fourth secondary endpoint" when the primary and secondary passed with flying colors (p=.001, .002). You're also stuck focusing in old, blended data which we don't have details on instead of the final, unblinded data.

The primary and secondary endpoints, which have definitely been accepted by EU and UK RAs, and now more likely than ever the FDA, are what dictate if the trial succeeded. And it did, no question. Even if the "fourth secondary endpoint" failed, this is minor.

All of this laid on top of the the dire situation GBM patients are in, it's clear this will be on the market within a year.